Hard to justify the 50 x MC of MSB compared to CYP. If the GvHD phase 2 trial continues to demonstrate outstanding efficacy and safety, it's safe to assume it will quickly replace ruxolitinib as SoC. Ruxo has many applications, with GvHD accounting for 17% of total income. That's circa $500M USD per annum. Frankly, the potential pipeline of indications appears immense.
Hard to justify the 50 x MC of MSB compared to CYP. If the GvHD...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.005(3.13%) |
Mkt cap ! $36.71M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $9.3K | 56.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 46113 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 56443 | 4 |
View Market Depth
| Last trade - 10.51am 18/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |